Life sciences news
-
OXURION NV secures EUR 10 million convertible bond financing from Kreos Capital and Pontifax Ventures
Monday November 22nd 2021
Read more
-
P95 appoints Henk Hoornaert as Chief Commercial Officer
Wednesday November 17th 2021
Read more
-
New study demonstrates Idylla™ EGFR Mutation Test (CE-IVD) shortens time to patient management decisions for patients with non-small cell lung cancer
Tuesday November 16th 2021
Read more
-
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
Monday November 15th 2021
Read more
-
Biotalys’ first biocontrol Evoca™ demonstrated to be excellent new tool for growers in 2021 independent field trials
Monday November 15th 2021
Read more
-
OXURION NV - First patient dosed in Part B of Phase 2 KALAHARI study evaluating multiple administrations of THR-149 versus aflibercept for treatment of Diabetic Macular Edema (DME)
Monday November 15th 2021
Read more
-
GSK and imec to collaborate on disruptive innovation in pharma
Tuesday November 9th 2021
Read more
-
reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program
Monday November 8th 2021
Read more
-
Become a flanders.bio member
Your news here?
-
Agomab Therapeutics to acquire Origo Biopharma
Thursday October 28th 2021
Read more
-
Thirona closes financing round with HERAN Partners and Borski Fund
Thursday October 28th 2021
Read more
-
reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase
Thursday October 21st 2021
Read more
More info?
Contact us
Ellen Telleir
Communication Coordinator
